Close Menu


The team published data on Monday highlighting its microfluidic chip's ability to help predict the clinical outcomes of glioblastoma patients. 

The firm has begun a trial for tests in non-small cell lung cancer and malignant melanoma and plans to launch an additional trial in glioblastoma.

The firm will use the proceeds to further a validation study  tracking the ability of its cell culture assay to predict patient response to cancer therapies.

Isoma, which launched last year, will use the funds to develop and clinically validate a molecular test for stratifying glioblastoma patients.

The two companies will work together to develop AroCell's TK 210 ELISA test for Green Cross Cell's therapeutic products and methods. 

Amoy will supply its CD95 IHC and CpG2 qPCR kits to develop a companion diagnostic for Canbridge's lead product targeting recurrent glioblastoma multiforme.